SureTrader
Interactive Brokers Advertisement
Home > Boards > US OTC > Medical - Drugs >

Akcea Therapeutics Inc (AKCA)

AKCA RSS Feed
Add AKCA Price Alert      Hide Sticky   Hide Intro
Moderator:
Search This Board: 
Last Post: 8/31/2017 2:10:31 PM - Followers: 3 - Board type: Free - Posts Today: 0

Akcea Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. The Company's drugs, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are all based on antisense technology developed by Ionis Pharmaceuticals, Inc. (Ionis). The Company's volanesorsen drug has completed a Phase III clinical program for the treatment of familial chylomicronemia syndrome (FCS) and is currently in Phase III clinical development for the treatment of familial partial lipodystrophy (FPL). The Company's clinical pipeline contains drugs with the potential to treat inadequately addressed lipid disorders beyond elevated LDL-C that are contributing to the dramatic increase in the incidence of cardiometabolic disease, such as elevated triglycerides, oxidized phospholipids and other lipoproteins, such as lipoprotein(a), or Lp(a).

Each of the four drugs in the Company's pipeline targets the specific ribonucleic acid, or RNA, that encodes for a unique protein associated with lipid dysfunction, robustly and selectively inhibiting the production of such protein. Additionally, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx utilize Ionis' advanced Ligand Conjugated Antisense (LICA) technology. The Company has completed a Phase I/II study with AKCEA-APO(a)-LRx in patients with hyperlipoproteinemia(a). The Company is engaged in developing AKCEA-ANGPTL3-LRx to treat multiple lipid disorders. The Company is engaged conducting a Phase I/II program for AKCEA-ANGPTL3-LRx in people with elevated triglycerides. The Company is also engaged developing AKCEA-APOCIII-LRx to inhibit the production of ApoC-III, the same protein inhibited by volanesorsen, for the broad population of patients having cardiometabolic disease due to their elevated triglyceride levels. The Company is engaged conducting a Phase I/II study of AKCEA-APOCIII-LRx.

The Company competes with uniQure N.V., Regeneron Pharmaceuticals, Inc. and Gemphire Therapeutics, Inc.http://www.reuters.com/finance/stocks/overview?symbol=AKCA.O

More Information:  
http://www.reuters.com/finance/stocks/overview?symbol=AKCA.O

Address
55 Cambridge Pkwy Ste 100
CAMBRIDGE, MA 02142-1219
United States - Map
+1-760-6032732 (Phone)
+1-302-6555049 (Fax)

Website links

SureTrader
Interactive Brokers Advertisement
AKCA
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
SureTrader
AKCA News: Akcea to Present at the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference 12/07/2017 07:00:00 AM
AKCA News: Current Report Filing (8-k) 11/30/2017 04:16:53 PM
AKCA News: Akcea and Ionis Announce Acceptance of Marketing Applications in U.S., EU and Canada for Volanesorsen for the Treatment of FC... 11/15/2017 07:00:00 AM
AKCA News: Akcea Initiates AKCEA-ANGPTL3-LRx Phase 2 Program in Patients with Rare Hyperlipidemias 11/13/2017 04:15:00 PM
AKCA News: Quarterly Report (10-q) 11/07/2017 05:27:57 PM
PostSubject
#18   So Volatile. Any thoughts on why the Thoro 08/31/17 02:10:31 PM
#17   Like how clean the board is .Some heavy Rodney213 08/08/17 09:58:13 PM
#16   Dropped heavy yesterday but bounced back some today. dinosaurbob 08/04/17 05:27:40 PM
#15   This is a volatile stock. Its finding Thoro 08/03/17 04:44:04 PM
#14   Closed at $15.43 today up 47 cents. dinosaurbob 08/02/17 06:14:47 PM
#13   Back up $1.02 today. This stock is dinosaurbob 07/31/17 04:48:49 PM
#12   WTH happened today? Down $1.52! dinosaurbob 07/28/17 05:24:35 PM
#11   Closed up 40 cents at $14.88 dinosaurbob 07/27/17 07:32:53 PM
#10   It was up big earlier but steadily dropping dinosaurbob 07/27/17 02:47:14 PM
#9   AKCA, Akcea and Ionis Announce Submission of Marketing Thoro 07/27/17 10:32:12 AM
#8   Closed up at $14.48 (5.16%). Nice! dinosaurbob 07/26/17 06:31:59 PM
#7   I know it dropped, but I like when Thoro 07/26/17 12:57:30 AM
#6   Yes, but it dropped to $13.77. I dinosaurbob 07/25/17 05:08:19 PM
#5   AKCA $16.30 looked great today! Thoro 07/25/17 05:01:01 PM
#4   I bought in at 9.88 and then doubled dinosaurbob 07/23/17 03:24:26 AM
#3   AKCA IPO doing great first 5 days of trading. Thoro 07/21/17 02:48:37 PM
#2   AKCA #MARKET NEWS Thoro 07/17/17 12:57:59 PM
#1   AKCA #MARKET NEWS Thoro 07/17/17 12:55:17 PM
PostSubject